Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 18/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13388913 | 0.88 | CFTR (0.48) | CFTRNPC1POLB | |
| SCHEMBL13388910 | 0.87 | CFTR (0.46) | CFTRNPC1POLBRAB9A | |
| SCHEMBL1074831 | 0.87 | CFTR (0.51) | CFTRNPC1POLBRAB9A | |
| SCHEMBL4116791 | 0.87 | CFTR (0.47) | CFTRNPC1POLBRAB9A | |
| SCHEMBL1080572 | 0.87 | CFTR (0.47) | CFTRNPC1POLBRAB9A | |
| SCHEMBL15109073 | 0.86 | CFTR (0.50) | CFTRNPC1POLBRAB9A | |
| SCHEMBL17029833 | 0.86 | CFTR (0.50) | CFTRNPC1POLBRAB9A | |
| SCHEMBL4114598 | 0.85 | CFTR (0.46) | CFTRNPC1POLBRAB9A | |
| SCHEMBL4111363 | 0.85 | CFTR (0.49) | CFTRNPC1POLBRAB9A | |
| SCHEMBL1070932 | 0.85 | CFTR (0.44) | CFTRNPC1POLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2980077-B1 | PYRIDYL DERIVATIVES AS CFTR MODULATORS | VERTEX PHARMA (US) | 2020-05-06 | — | — | EP | disclosed |
| EP-2980077-A1 | PYRIDYL DERIVATIVES AS CFTR MODULATORS | Vertex Pharmaceuticals Incorporated (US) | 2016-02-03 | — | — | EP | disclosed |
| EP-2980077-A1 | PYRIDYL DERIVATIVES AS CFTR MODULATORS | Vertex Pharmaceuticals Incorporated (US) | 2016-02-03 | — | — | EP | disclosed |
| EP-2615085-B1 | Pyridyl derivatives as CFTR modulators | VERTEX PHARMA (US) | 2015-08-26 | — | — | EP | disclosed |
| US-8889875-B2 | Pyridyl derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889875-B2 | Pyridyl derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-11-18 | — | — | US | disclosed |
| US-20130317020-A1 | Pyridyl Derivatives as CFTR Modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-11-28 | — | — | US | disclosed |
| EP-2271621-B1 | PYRIDYL DERIVATIVES AS CFTR MODULATORS | VERTEX PHARMA (US) | 2013-11-20 | — | — | EP | disclosed |
| US-8524910-B2 | Pyridyl derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524910-B2 | Pyridyl derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-03 | — | — | US | disclosed |
| US-20120270869-A1 | PYRIDYL DERIVATIVES AS CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-25 | — | — | US | disclosed |
| US-8227615-B2 | Pyridyl derivatives as CFTR modulators | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2012-07-24 | — | — | US | disclosed |
| US-8227615-B2 | Pyridyl derivatives as CFTR modulators | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2012-07-24 | — | — | US | disclosed |
| US-8227615-B2 | Pyridyl derivatives as CFTR modulators | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2012-07-24 | — | — | US | disclosed |
| EP-2271621-A1 | PYRIDYL DERIVATIVES AS CFTR MODULATORS | Vertex Pharmaceuticals Incorporated (US) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009123896-A1 | PYRIDYL DERIVATIVES AS CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-10-08 | — | — | WO | disclosed |
| WO-2009123896-A1 | PYRIDYL DERIVATIVES AS CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-10-08 | — | — | WO | disclosed |
| US-20090246137-A1 | PYRIDYL DERIVATIVES AS CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090246137-A1 | PYRIDYL DERIVATIVES AS CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090246137-A1 | PYRIDYL DERIVATIVES AS CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090246137-A1 | PYRIDYL DERIVATIVES AS CFTR MODULATORS | CFTR, ABCC4, ABCB1 | CFTR 1/4885NPC1 81/4885POLB 1603/4885 |
| US-20130317020-A1 | Pyridyl Derivatives as CFTR Modulators | CFTR, ABCC4, ABCB1 | CFTR 1/4885NPC1 81/4885POLB 1603/4885 |
| US-20120270869-A1 | PYRIDYL DERIVATIVES AS CFTR MODULATORS | CFTR, ABCC4, ABCB1 | CFTR 1/4885NPC1 81/4885POLB 1603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.